First Wave BioPharma goes public at $6M

First Wave BioPharma, a company specializing in treating gastrointestinal disease, has priced its public offering at $6 million.

The initial public offering includes about 3.4 million shares of its common stock priced at $1.745 per share and is expected to close on Oct. 11. H.C. Wainright & Co. is acting as the exclusive placement agent for the offering, according to the Oct. 6 First Wave news release provided to Becker's.

The company plans to use the capital to make the final payment owed to former stockholders of First Wave and for general working capital. 

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars